Board of Directors

Chris Garabedian, Chairman
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.

Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

Chris serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues. Chris is also on the Board of Directors of MassBio and serves as a Senior Advisor for the Boston Consulting Group.

Fred Callori
Fred joined Xontogeny in September 2017 as SVP, Corporate Development. Fred’s responsibilities include due diligence, deal structuring and negotiation, company formation, and the operational oversight and management of Xontogeny’s seed investments. He provides corporate governance, transactional and strategic advice to Xontogeny’s portfolio of companies and serves on several portfolio company Boards. In 2018, Fred joined the Perceptive Xontogeny Venture Fund to support fund investments, including continued investments in companies seeded and incubated at Xontogeny.

Prior to joining Xontogeny, Fred was a Partner in the Life Science and Emerging Companies practices of Choate, Hall & Stewart LLP, a Boston law firm ranked among the most active firms worldwide for private equity and venture capital deals. During his 20-year tenure at Choate, Fred developed deep expertise in the formation, structure, financing and overall corporate development of early stage and emerging life science companies, including representing leading venture capital and institutional investment firms focused on investing in the sector.

Fred holds a JD from Boston University School of Law and a BA in Economics from Binghamton University.

Jonathan Violin, Ph.D.
Jonathan joined Quellis shortly after its incorporation to lead its launch and growth. He is a partner at Viridian LLC, a biotech incubator that builds virtual drug discovery companies to pursue product-focused drug discovery hypotheses. Prior to joining Viridian, Jonathan co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. While there, he held a series of roles including leadership of discovery biology, investor relations, corporate strategy, and scientific affairs. He has helped identify and progress four novel molecules in to clinical development, including one program granted Breakthrough Therapy Designation by the FDA. He also has experience in alliance management, business development, and regulatory interactions including team lead and moderator for a new chemical entity FDA Advisory Committee. Jonathan has co-authored over 45 peer-reviewed publications. He holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.